000 01111 a2200325 4500
005 20250518061030.0
264 0 _c20200521
008 202005s 0 0 eng d
022 _a2173-5778
024 7 _a10.1016/j.ad.2018.05.022
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMonteiro, A F
245 0 0 _aAggressive Inferior Eyelid Basal Cell Carcinoma: Advantage of Neoadjuvant Vismodegib.
_h[electronic resource]
260 _bActas dermo-sifiliograficas
_cDec 2019
300 _a863-865 p.
_bdigital
500 _aPublication Type: Case Reports; Letter
650 0 4 _aAged, 80 and over
650 0 4 _aAnilides
_xtherapeutic use
650 0 4 _aCarcinoma, Basal Cell
_xdrug therapy
650 0 4 _aEyelid Neoplasms
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aNeoadjuvant Therapy
650 0 4 _aPyridines
_xtherapeutic use
700 1 _aRato, M
700 1 _aTrigo, M
700 1 _aMartins, C
773 0 _tActas dermo-sifiliograficas
_gvol. 110
_gno. 10
_gp. 863-865
856 4 0 _uhttps://doi.org/10.1016/j.ad.2018.05.022
_zAvailable from publisher's website
999 _c30106028
_d30106028